ScreenerHero
NAMSNewAmsterdam Pharma Company N.V. Ordinary Shares
NAS · US · Healthcare · Biotechnology · newamsterdampharma.com
28.00USD-1.86%Mkt Cap: 3.41B $P/E: —

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl…

Industry Peers

Biotechnology
Screen all
VX1
Vertex Pharmaceuticals Incorporated
$130.23BUSDP/E 32.1
VRTX
Vertex Pharmaceuticals Incorporated
$139.84BUSDP/E 32.2
REGN
Regeneron Pharmaceuticals, Inc.
$85.11BUSDP/E 20.4
MRNA
Moderna, Inc.
$69.62BUSD
ARGX
ARGENX SE
$60.19BUSDP/E 39.1
UCB
UCB SA
$45.16BUSDP/E 19.2
RVMD
Revolution Medicines, Inc.
$46.01BUSD
ONC
BeOne Medicines AG
$41.76BUSDP/E 66.2
RPRX
Royalty Pharma Plc Class A
$35.67BUSDP/E 33.2
ALNY
Alnylam Pharmaceuticals, Inc.
$32.46BUSDP/E 42.3
INSM
Insmed Incorporated
$28.53BUSD
22UA
BioNTech SE
$26.14BUSD
INCY
Incyte Corporation
$25.79BUSDP/E 16.2
GMAB
Genmab A/S
$20.83BUSDP/E 26.3
GMAB
Genmab A/S
$19.17BUSDP/E 26.2
ASND
Ascendis Pharma A/S
$17.03BUSDP/E 20.0
BBIO
BridgeBio Pharma, Inc.
$16.41BUSD
EXEL
Exelixis, Inc.
$13.48BUSDP/E 17.1
BMRN
BioMarin Pharmaceutical Inc.
$13.42BUSDP/E 187.4
CORT
Corcept Therapeutics Incorporated
$12.87BUSDP/E 264.5

Key Statistics

Company
Market Cap3.41B $
Enterprise Value2.69B $
Revenue (TTM)7.12M $
Gross Profit7.12M $
Net Income (TTM)-203.82M $
Revenue/Share0.0590 USD
Last Price28.00 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees100
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-17.81
PEG—
EV/EBITDA-11.01
EV/Revenue377.33
P/S456.06
P/B5.18
EPS (TTM)-2.10
EPS (Forward)-1.56
52W Range
26.5466% of range28.76
52W High28.76 USD
52W Low26.54 USD
Profitability
Gross Margin100.00%
Oper. Margin-1752.61%
EBITDA Margin0.00%
Profit Margin-905.74%
ROE-29.82%
ROA-26.49%
Growth
Revenue Growth-80.70%
Earnings Growth—
Cash Flow & Leverage
Operating CF-147.78M $
CapEx (TTM)246.00K $
FCF Margin-636.97%
FCF Yield-1.33%
Net Debt-633.77M $
Net Debt/EBITDA2.60
Balance Sheet
Debt/Equity0.00
Current Ratio9.03
Quick Ratio8.76
Book Value/Sh5.367 USD
Cash/Share5.303 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)52.04 USD
Upside (mean)+85.8%
Target Range38.50 USD – 60.79 USD
$38.50+85.8% to mean$60.79
# Analysts15
Ownership
Shares Out.119.54M
Float82.90M
Insiders0.89%
Institutions106.15%
Short Interest
Short Ratio10.5d
Short % Float9.93%
Short % Out.8.47%
Shares Short9.96M
Short (prev mo.)9.09M
Technical
SMA 5030.61 (-8.5%)
SMA 20033.19 (-15.6%)
Beta0.11
S&P 52W Chg18.16%
Avg Vol (30d)919.27K
Avg Vol (10d)1.12M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—